Gaxiola E, Ramírez-Sánchez U

Language: Spanish
References: 25
Page: 269-274
PDF size: 110.76 Kb.

ABSTRACT

The mortality rate for cardiogenic shock has decreased over the past decade. These improvements are presumed to reflect increased use of intraaortic ballon counterpulsation and coronary reperfusion strategies which, by restoring patency to the infarct-related artery, can limit infarct size. Despite these therapeutic measures, mortality rates remain elevated. Current strategies are aimed at decreasing reperfusion times and measures to preserve and prolong myocardial cell viability.

REFERENCES

1. GOLDBERG, RJ, GORE, JM, THOMPSON, CA, GURWITZ JH: Recent magnitude of and temporal trends (1994-1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: The second National Registry of Myocardial Infarction. Am Heart J 2001; 141: 65.

2. HOLMES DR JR, BATES ER, KLEINMAN NS, ET AL: Contemporary reperfussion therapy for cardiogenic shock: The GUSTO-I trial experience. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995; 26: 668.

3. HOLMES DR JR, BERGER PB, HOCHMAN, JS ET AL: Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 1999; 100: 2067.

4. GOLDBERG RJ, GORE JM, ALPERT JS, ET AL: Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community wide perspective, 1975-1988. N Engl J Med 1991; 325: 1117.

5. HASDAI D, HARRINGTON RA, HOCHMAN JS, ET AL: Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol 2000; 36: 685.

6. HANDS ME, RUTHERFORD JD, MULLER JE, ET AL: The in-hospital development of cardiogenic shock after myocardial infarction: Incidence, predictors of occurrence, outcome and prognostic factors. J Am Coll Cardiol 1989; 14: 40.

7. HOCHMAN JS, SLEEPER LA, WHITE HD, ET AL: Oneyear survival following early revascularization for cardiogenic shock. JAMA 2001; 285: 190-192.

8. GIRI S, MITCHEL J, AZAR RR, ET AL: Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2002; 89: 126.

9. CHAN AW, CHEW DP, BHATT DL, ET AL: Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2002; 89: 132.

10. ANTMAN EM, ANBE DT, ARMSTRONG PW, ET AL: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588.

11. WEBB JG, SANBORN TA, SLEEPER SCD, CARERE RG, BULLER CE, SLATER JN, ET AL: Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. Am Heart J 2001; 141: 964-70.

12. HOCHMAN JS: Cardiogenic shock complicating acute myocardial infarction. Expanding the paradigm. Circulation 2003; 107: 2998-3002.

13. MARTÍNEZ-RÍOS MA, ROSAS M, GONZÁLEZ H, ET AL: Relevance of the combined TIMI flow/perfusion index to effective assessment of reperfussion regimens with or without tirofiban in ST-elevation myocardial infarction. Insights from SASTRE-STEMI study, a randomized clinical trial. Am J Cardiol 2004; 93: 280-287.

14. MONTALESCOT G, BORENTAIN M PAYOT L, ET AL : Early vs late administration of glycoprotein IIb/ IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction. A meta-analysis. JAMA 2004; 292: 362-66.

15. GOROG DA, FOALE RA, MALIK I: Distal myocardial protection during percutaneous coronary intervention. When and where? J Am Coll Cardiol 2005; 46: 1434-45.

16. BERANEK JT: C-reactive protein and complement in myocardial infarction and postinfarction heart failure. Eur Heart J 1997; 18: 1834-1836.

17. MATHEY D, SCHOFER J, SCHAFER HJ, HAMDOCH T, JOACHIM HC, RITGEN A. Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfussion. Eur Heart J 1994; 15: 418-423

18. MAHAFFEY KW, GRANGER CB, NICOLAU JC, RUZYLLO W, WEAVER WD, THEROUX P, ET AL: Effect of Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolisis in acute myocardial infarction. The COMPLY Trial. Circulation 2003; 108: 1176-83.

19. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction. The COMMA Trial. Circulation 2003; 108: 1184-90.

20. COTTER G, KALUSKI E, MILO O, BLATT A, SALAH A, HENDLER A, ET AL: LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogénico shock. A prospective randomized study. Eur Heart J 2003; 24: 1287-95.

21. The Hypothermia after Cardiac Arrest Study Group. Mild Therapeutic Hypothermia to Improve the Neurologic Outcome after Cardiac Arrest. N Engl J Med 2002; 346: 549-556.

22. ROSS AM, GIBBONS RJ, STONE GW, KLONER RA, ALEXANDER RW for the AMISTAD-II Investigators A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Adenosine as an Adjunct to Reperfussion in the Treatment of Acute Myocardial Infarction (AMISTAD-II). J Am Coll Cardiol 2005; 45: 1775-80.

23. The CREATE-ECLA Trial Group Investigators*. Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction: The CREATE-ECLA Randomized Controlled Trial. JAMA 2005; 293: 437-446.

24. KLONER RA, REZKALLA SH: Cardiac protection during acute myocardial infarction: where do we stand in 2004? J Am Coll Cardiol 2004; 44: 276-86.

25. DIMMELER S, ZEIHER AM: Wanted! The best cell for cardiac regeneration. J Am Coll Cardiol 2004; 44: 464-466.